Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach that offers “a promising therapeutic strategy”.

The results are published in ‘Blood’ by researchers from the Josep Carreras Leukaemia Research Institute and the Hospital Universitario 12 de Octubre – Spanish National Cancer Research Center (CNIO), among other institutions.

“Although in the preclinical stage, this research is a first step toward improving treatments for B-ALL patients”, authors say. “The goal is to enhance the effectiveness of CAR-T therapy and reduce relapses”.